See more : Yellowstone Acquisition Company (YSAC) Income Statement Analysis – Financial Results
Complete financial analysis of Aditxt, Inc. (ADTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aditxt, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cosan S.A. (CSAN3.SA) Income Statement Analysis – Financial Results
- TMM, Inc. (TMMI) Income Statement Analysis – Financial Results
- PT Perusahaan Perkebunan London Sumatra Indonesia Tbk (PPLFF) Income Statement Analysis – Financial Results
- Sensei Biotherapeutics, Inc. (SNSE) Income Statement Analysis – Financial Results
- Tokyo Cosmos Electric Co., Ltd. (6772.T) Income Statement Analysis – Financial Results
Aditxt, Inc. (ADTX)
About Aditxt, Inc.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 645.18K | 933.72K | 105.03K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 756.84K | 766.78K | 77.98K | 17.77K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -111.66K | 166.94K | 27.06K | -17.77K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -17.31% | 17.88% | 25.76% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.07M | 7.27M | 5.04M | 937.97K | 175.44K | 525.00K | 0.00 |
| General & Administrative | 18.61M | 15.99M | 22.08M | 7.85M | 5.69M | 5.04M | 851.94K |
| Selling & Marketing | 269.28K | 1.85M | 334.98K | 81.99K | 551.00 | 39.84K | -638.96K |
| SG&A | 18.88M | 17.84M | 22.42M | 7.93M | 5.70M | 5.08M | 212.99K |
| Other Expenses | 0.00 | 58.96K | 14.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.95M | 25.10M | 27.46M | 8.87M | 5.87M | 5.61M | 212.99K |
| Cost & Expenses | 26.71M | 25.87M | 27.54M | 8.87M | 5.87M | 5.61M | 212.99K |
| Interest Income | 10.17K | 57.35K | 3.10K | 563.00 | 1.93K | 0.00 | 0.00 |
| Interest Expense | 6.39M | 2.29M | 1.94M | 310.08K | 1.93K | 79.77K | 0.00 |
| Depreciation & Amortization | 542.58K | 535.98K | 476.24K | 17.77K | 5.87M | 5.61M | 851.94K |
| EBITDA | -25.46M | -24.83M | -43.96M | -8.85M | 45.00K | 0.00 | 638.96K |
| EBITDA Ratio | -3,945.89% | -2,600.78% | -25,663.68% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -26.06M | -24.94M | -27.43M | -8.87M | -5.87M | -5.61M | -212.99K |
| Operating Income Ratio | -4,039.58% | -2,670.64% | -26,120.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.33M | -2.17M | -4.44M | -277.02K | 43.07K | -79.77K | 0.00 |
| Income Before Tax | -32.39M | -27.65M | -46.37M | -9.15M | -5.83M | -5.69M | -212.99K |
| Income Before Tax Ratio | -5,020.40% | -2,961.28% | -44,148.91% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 543.94K | 1.94M | 310.08K | 1.93K | -161.14K | -851.94K |
| Net Income | -32.38M | -28.19M | -48.31M | -9.46M | -5.83M | -5.69M | -212.99K |
| Net Income Ratio | -5,018.92% | -3,019.53% | -45,994.56% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -108.15 | -608.04 | -5.06K | -1.46K | -2.25K | -2.90K | -82.35 |
| EPS Diluted | -108.15 | -608.04 | -5.06K | -1.46K | -2.25K | -2.90K | -82.35 |
| Weighted Avg Shares Out | 302.36K | 46.37K | 9.55K | 6.49K | 2.59K | 1.96K | 2.59K |
| Weighted Avg Shares Out (Dil) | 302.36K | 46.37K | 9.55K | 6.49K | 2.59K | 1.96K | 2.59K |
Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee...
Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023
RICHMOND, Va. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- #autoimmunity--Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the Aditxt management team will...
Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the...
Aditxt stock price has plummeted: avoid at all cost
Aditxt (NASDAQ: ADTX) stock price has been in the spotlight in the past few days. The shares plunged by more than 24% on Friday, one of its worst days this year.
Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and...
Why Is Aditxt (ADTX) Stock Up 10% Today?
Shares of biotechnology firm Aditxt (NASDAQ: ADTX ) — which specializes in therapeutics and technologies that monitor and modulate the immune system — popped up 25% on Friday morning before paring some gains in the early afternoon session. Nevertheless, ADTX...
Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale
RICHMOND, Va.--(BUSINESS WIRE)-- #autoimmunity--Aditxt®, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system, is pleased to provide an important update...
CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023
RICHMOND, Va.--(BUSINESS WIRE)--First paragraph, first sentence of release should read: Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect...
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock...
7 Hot Penny Stocks Under $1.10 To Watch This Week
Penny stocks to buy for under $1 but are they worth the risk? The post 7 Hot Penny Stocks Under $1.10 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports